메뉴 바로가기
주메뉴 바로가기
컨텐츠 바로가기
Company
About the CEO
Executive Committee
Values and Vision
History
Business Strategy
Employment Information
Contact Us
Business
Summary
Bio Drug Business
Synthetic Biology Business
Pipeline
Innovative new drug platform technology and research
BHD1028
ECN1028
ECN0424
ECN0827
ECN3003
News
Notices
Press Releases
Archive
Board
Korean
English
Company
About the CEO
Executive Committee
Values and Vision
History
Business Strategy
Employment Information
Contact Us
Business
Summary
Bio Drug Business
Synthetic Biology Business
Pipeline
Innovative new drug platform technology and research
BHD1028
ECN1028
ECN0424
ECN0827
ECN3003
News
Notices
Press Releases
Archive
Board
KR
EN
Company
About the CEO
Executive Committee
Values and Vision
History
Business Strategy
Employment Information
Contact Us
Business
Summary
Bio Drug Business
Synthetic Biology Business
Pipeline
Innovative new drug platform technology and research
BHD1028
ECN1028
ECN0424
ECN0827
ECN3003
News
Notices
Press Releases
Archive
Board
News
Notices
Press Releases
Archive
Board
Archive
No
Subject
Writer
Date
3
Enhanced Immunomodulation, Anti-Apoptosis, and Improved Tear Dynamics of (PEG)-BHD1028, a Novel Adiponectin Receptor Agonist Peptide, for Treating Dry Eye Disease
Encuragen
2023-01-02
2
[Eucuragen]PEG-BHD1028 Peptide Regulates Insulin Resistance and Fatty
Encuragen
2021-11-29
1
[PLOS ONE] Discovery of a novel potent peptide agonist to adiponectin receptor 1
Encuragen
2021-11-29
ALL
Subject
Contents
Writer
Please enter your search term
Search